Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: A review

Current Medicinal Chemistry

Volumn 18, Issue 11, 2011, Pages 1704-1722

  Yadav, R K ^a   Gupta, S P ^a   Sharma, P K ^a   Patil, V M ^b  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^b BHARAT INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Hydroxamates; Hydroxamic acids; Matrix metalloproteinase inhibitors; Matrix metalloproteinases

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ALPHA PIPERIDINE ALPHA SULFONE HYDROXAMATE; BATIMASTAT; HYDROXAMIC ACID DERIVATIVE; HYDROXYLAMINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; SC 276; SC 77774; SC 77964; SC 78080; SD 2590; SULFONAMIDE; UNCLASSIFIED DRUG; VORINOSTAT; ZINC ION;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

HUMANS; HYDROXAMIC ACIDS; LIGANDS; MATRIX METALLOPROTEINASES; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

EID: 79955698736     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795471329     Document Type: Article

References (57)

1. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): Chemicalbiological functions and (Q)SARs. Bioorg. Med. Chem. 2007, 15, 2223-2268. (Pubitemid 46240907)
2. Aranapakam, V.; Grosu, G. T.; Davis, J. M.; Hu, B.; Ellingboe, J.; Baker, J. L.; Skotnicki, J. S.; Zask, A.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.; Walter, T.; Jin, G.; Cowling, R. Synthesis and structure-activity relationship of -- sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem. 2003, 46, 2361-2375.
3. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Chem. Biol. 2005, 12,181-189.
4. Amin, E. A.; Welsh, W. J. Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin- 1 (MMP-3) inhibitors: applying a "Divide and Conquer" strategy. J. Med. Chem., 2001, 44, 3849-3855. (Pubitemid 33051475)
5. Raspollini, M. R.; Castiglione, F.; Degl'Innocenti, D. R.; Garbini, F.; Coccia, M. E.; Taddei, G. L. Difference in expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in patients with persistent ovarian cysts. Fertil. Steril. 2005, 84, 1049-1052. (Pubitemid 41414609)
6. Venkatesan, A. M.; Davis, J. M.; Grosu, G. T.; Baker, J.; Zask, A.; Levin, J. I.; Ellingboe, J.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Jin, G.; Xu, W.; McCarthy, D. J.; Barone, D. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl sulfinyl and sulfonyl alkyl hydroxamates as tumor necrosis factor-- converting enzyme and matrix metalloproteinase inhibitors. J. Med. Chem. 2004, 47, 6255-6269. (Pubitemid 39587250)
7. Brown, S.; Meroueh, S. O.; Fridman, R.; Mobashery, S. Quest for selectivity in inhibition of matrix metalloproteinases. Curr. Top Med. Chem. 2004, 4, 1227-38. (Pubitemid 39172334)
8. Cheng, M.; De, B.; Pikul, S.; Almstead, N. G.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Chen, L.; Dunaway, C. M.; Gu, F.; Dowty, M. E.; Mieling, G. E.; Janusz, M. J.; Wang- Weigand, S. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J. Med. Chem. 2000, 43, 369-380. (Pubitemid 30102077)
9. Kontogiorgis, C. A.; Papaioannou, P.; Hadjipavlou-Litina, D. J. Matrix metalloproteinase inhibitors: A review on pharmacophore mapping and (Q)Sars results. Curr. Med. Chem., 2005, 12, 339-355. (Pubitemid 40305624)
10. Gupta, S. P. Quantitative structure-activity relationship studies on zinccontaining metalloproteinase inhibitors. Chem. Rev. 2007, 107, 3042-3087. (Pubitemid 47162904)
11. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: Current status and future prospects. J. Med. Chem., 2000, 43, 305-341. (Pubitemid 30102072)
12. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, J. H. Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev., 1999, 99, 2735-2776.
13. Overall, C. M.; López-Otín, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-72. (Pubitemid 37328917)
14. Benoit de Coignac, A.; Elson, G.; Gauchat, J. -F. Pierre Fabre Medicament, France, Patent No. WO 2001016335.
15. Supuran, C. T.; Scozzafava, A. In proteinase and peptidase inhibition: Recent potential targets for drug development; Smith, H. J.; Simons, C.; Eds; Taylor & Francis: London, New York, 2002, 35-61.
16. Johnson, W. H.; Roberts, N. A. and Borkakoti, N. J. Enzyme Inhib. 1987, 2, 1-22.
17. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97, 1359-1472. (Pubitemid 127659602)
18. Shuttleworth, S. In Advances in Drug Discovery Techniques. Harvey, A. L.; Ed; John-Wiley & Sons Ltd.: New York, 1998, 115.
19. Whittakar, M. Discovery of protease inhibitors using targeted libraries. Curr. Opin. Chem. Biol. 1998, 2, 386-396.
20. Flipo, M.; Charton, J.; Hocine, A.; Dassonneville, S.; Deprez, B.; Deprez- Poulain, R. Hydroxamates: relationships between structure and plasma stability J. Med. Chem. 2009, 52, 6790-6802.
21. Grant, S.; Easley, C.; Kirkpatrick, P. Vorinostat. Nat. Rev. Drug Discov. 2007, 6, 21-22.
22. Cuniasse, P.; Devel, L.; Makaritis, A.; Beau, F.; Georgiadis, D.; Matziari, M; Yiotakis, A.; Dive, V. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie. 2005, 87, 393-402. (Pubitemid 40387619)
23. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34, 14012-14020.
24. Bottomley, K. M.; Johnson, W. H. and Walter, D. S. J. Enzyme Inhib. 1998, 13, 79-101.
25. Levin, J. I. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE Curr. Top Med. Chem. 2004, 4, 1289-1310. (Pubitemid 39172338)
26. Roedern, G. E.; Grams, R.; Brandstetter, H.; Moroder, L. Design and synthesis of malonic acid-based inhibitors of human neutrophil collagenase (MMP8). J. Med. Chem. 1998, 41, 339-345. (Pubitemid 28079788)
27. Krumme, D.; Wenzel, H.; Tschesche, H. Hydroxamate derivatives of substrate- analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases FEBS Lett. 1998, 436, 209-212. (Pubitemid 28468557)
28. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carrol, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O. Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532. (Pubitemid 27347016)
29. Jeng, A. Y.; Chou, M.; Parker, D. T. Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase Bioorg. Med. Chem. Lett. 1998, 8, 897-902. (Pubitemid 28206599)
30. Hannessian, S.; Bouzbouz, S.; Boudon, A.; Tucker, G. C.; Peyroulan, D. Picking the S1, S1- and S2- pockets of matrix metalloproteinases: a niche for potent acyclic sulfonamide inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1691-1696
31. Ref. 15 and references therein.
32. Levin, J. I.; Du, M. T.; Di Joseph, J. F.; Killar, L. M.; Sung, A.; Walter, T.; Sharr, M. A.; Roth, C. E.; Moy, F. J.; Powers, R.; Jin, G.; Cowling, R.; Skotnicki, J. S. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3- position. Bioorg. Med. Chem. Lett. 2001, 11, 235-238. (Pubitemid 32099648)
33. Nuti, E.; Casalini, F.; Avramova, S. I.; Santamaria, S.; Cercignani, G.; Marinelli, L.; Pietra, V. L.; Novellino, E.; Orlandini, E.; Nencetti, S.; Tuccinardi, T.; Martinelli, A.; Lim, N. H.; Visse, R.; Nagase, H.; Rossello, A. N-Oisopropyl sulfonamide-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J. Med. Chem. 2009, 52, 4757-4773.
34. Neumann, U.; Kubota, H.; Frei, K.; Ganu, V.; Leppert, D. Characterization of mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal. Biochem. 2004, 328, 166-173. (Pubitemid 38542933)
35. Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balzano, F.; Uccello- Barretta, G.; Murphy, G.; Rossello, A. Amber force field implementation, molecular modeling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2- (N-isopropoxybiphenyl-4-ylsulfonamido)-3- methylbutanamides. Bioorg. Med. Chem. 2006, 14, 4260-4276.
36. Rossello, A.; Nuti, E.; Carelli, P.; Orlandini, E.; Macchia, M.; Nencetti, S.; Zandomeneghi, M.; Balzano, F.; Uccello Barretta, G.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. N-i-propoxy-N- biphenylsulfonyl aminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg. Med. Chem. Lett. 2005, 15, 1321-1326. (Pubitemid 40268984)
37. Wada, C. K.; Holms, J. H.; Curtin, M. L.; Dai, Y.; Florjancic, A. S.; Garland, R. B.; Guo, Y.; Heyman, H. R.; Stacey, J. R.; Steinman, D. H.; Albert, D. H.; Bouska, J. J.; Elmore, I. N.; Goodfellow, C. L.; Marcotte, P. A.; Tapang, P.; Morgan, D. W.; Michaelides, M. R.; and Davidsen, S. K. Phenoxyphenyl sulfone N- formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 2002, 45, 219-232. (Pubitemid 34038556)
38. Michaelides, M. R.; Dellaria, J. F.; Gong, J.; Holms, J. H.; Bouska, J. J.; Stacey, J.; Wada, C. K.; Heyman, H. R.; Curtin, M. L.; Guo, Y.; Goodfellow, C. L.; Elmore, I. B.; Albert, D. H.; Magoc, T. J.; Marcotte, P. A.; Morgan, D. W.; Davidsen, S. K. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1553-1556. (Pubitemid 32703561)
39. Yang, S. M.; Scannevin, R. H.; Wang, B.; Burke, S. L.; Wilson, L. J.; Karnachi, P. Rhodes, K. J.; Lagu, B.; and Murray, W. V. N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1. design, synthesis, and lead identification. Bioorg. Med. Chem. Lett. 2008, 18, 1135-1139. (Pubitemid 351179319)
40. Peterson, J. T. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Failure Rev. 2004, 9, 63-79. (Pubitemid 38202142)
41. Brown, P. D. Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999,107, 174-180. (Pubitemid 29133538)
42. Rossello, A.; Nuti, E.; Orlandini, E.; Carelli, P.; Rapposelli, S.; Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg. Med. Chem. 2004, 12, 2441-2450. (Pubitemid 38471726)
43. Rossello, A.; Nuti, E.; Catalani, M. P.; Carelli, P.; Orlandini, E.; Rapposelli, S.; Tuccinardi, T.; Atkinson, S. J.; Murphyb, G.; Balsamoa, A. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg. Med. Chem. Lett. 2005, 15, 2311-2314. (Pubitemid 40523092)
44. Ma, D.; Wu, W.; Yang, G.; Li, J.; Li, J.; Ye, Q. Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 47-50. (Pubitemid 38010191)
45. Takahashi, K.; Ikura, M.; Habashita, H.; Nishizaki, M.; Sugiura, T.; Yamamoto, S.; Nakatani, S.; Ogawa, K.; Ohno, H.; Nakai, H.; Toda, M. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach. Bioorg. Med. Chem. 2005, 13, 4527-4543. (Pubitemid 40813241)
46. Nakatani, S.; Ikura, M.; Yamamoto, S.; Nishita, Y.; Itadani, S.; Habashita, H.; Sugiura, T.; Ogawa, K.; Ohno, H.; Takahashi, K.; Nakai, H.; Toda, M. Design and synthesis of novel metalloproteinase inhibitors. Bioorg. Med. Chem. 2006, 14, 5402-5422. (Pubitemid 43903243)
47. Ikura, M.; Nakatani, S.;Yamamoto, S.; Habashita, H.; Sugiura, T.; Takahashi, K.; Ogawa, K.; Ohno, H.; Nakai, H.; Toda, M. Discovery of a new chemical lead for a matrix metalloproteinase inhibitor. Bioorg. Med. Chem. 2006, 14, 4241-4252.
48. Becker, D. P.; Villamil, C. I.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; DeCrescenzo, G. A.; Freskos, J. N.; Getman, D. P.; Hockerman, S.; Heintz, R.; Howard, S. C.; Li, M. H.; McDonald, J. J.; Carron, C. P.; Funckes- Shippy, C. L.; Mehta, P. P.; Munie, G. E.; Swearingen, C. A. Synthesis and structure-activity relationships of and piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. J. Med. Chem., 2005, 48, 6713-6730. (Pubitemid 41504727)
49. Becker, D. P.; Barta, T. E.; Bedell, L.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Mischke, B.; Munie, G. E.; Swearingen, C. Villamil, C. I. Amino sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2001, 11, 2719-2722. (Pubitemid 32925302)
50. Becker, D. P.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Munie, G. E.; Swearingen, C. Alkyl-amino sulphone hydroxamates as potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2001, 11, 2723-2725. (Pubitemid 32925303)
51. Becker, D.; Barta, T.; Bedell, L.; Boehm, T.; Carron, C.; De- Crescenzo, G.; Freskos, J.; Funckes-Shippy, C.; Getman, D.; Hockerman, S.; Li, M.; McDonald, J.; Mehta, P.; Munie, G.; Rico, J.; Shieh, H.; Stevens A.; Swearingen, C. Design and synthesis of potent and orally active MMP-1 sparing matrix metalloproteinase inhibitors with efficacy in antitumor models. oral presentation at the 222nd ACS National Meeting, Chicago, IL, August 26-30, 2001. Abstr. Pap. Am. Chem. Soc., Medi 018.
52. Barta, T. E.; Becker, D. P.; Boehm, T. L.; DeCrescenzo, G. A.; Villamil, C. I.; McDonald, J. J.; Freskos, J. N.; Getman, D. P. Preparation of arylsulfonyl heterocyclyl hydroxamic acids and related compounds as matrix metalloproteases inhibitors. U. S. Patent 6,541,489, 2003. PCT Int. Appl. WO 9925687 A1 990527 CAN 131:18929; AN 1999:350651.
53. Natchus, M. G.; Bookland, R. G.; De, B.; Almstead, N. G.; Pikul, S.; Janusz, M. J.; Heitmeyer, S. A.; Hookfin, E. B.; Hsies, L. C.; Dowty, M. E.; Dietsch, C. R.; Patel, V. S.; Garver, S. M.; Gu, F.; Pokross, M. E.; Mieling, G. E.; Baker, T. R.; Foltz, D. J.; Peng, S. X.; Bornes, D. M.; Strojnowski, M. J.; Taiwo, Y. O. Development of new hydroxamates matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J. Med. Chem. 2000, 43, 4948-4963. (Pubitemid 32039016)
54. Knight, C. G.; Willenbrock, F.; Murphy, G. A. A novel coumarin- labeled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
55. Okada, Y.; Nagase, H.; Harris, E. D. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components: purification and characterization. J. Biol. Chem. 1986, 261, 14245-14255. (Pubitemid 17196334)
56. Kolodziej, S. A.; Hockerman, S. L.; Boehm, T. L.; Carroll, J. N.; DeCrescenzo, G. A.; McDonald, J. J.; Mischke, D. A.; Munie, G. E.; Fletcher, T. R.; Rico, J. G.; Stehle, N. W.; Swearingen, C.; Becker, D. P. Orally bioavailable dual MMP-1/MMP- 14 sparing, MMP-13 selective sulfone hydroxamates. Bioorg. Med. Chem. Lett. 2010, 20, 3557-3560.
57. Becker, D. P.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; Bond, B. R.; Carroll, J.; Carron, C. P.; DeCrescenzo, G. A.; Easton, A. M.; Freskos, J. N.; Funckes-Shippy, C. L.; Heron, M.; Hockerman, S.; Howard, C. P.; Kiefer, J. R.; Li, M. H.; Mathis, K. J.; McDonald, J. J.; Mehta, P. P.; Munie, G. E.; Sunyer, T.; Swearingen, C. A.; Villamil, C. I.; Welsch, D.; Williams, J. M.; Yu, Y.; Yao, J. Orally active MMP-1 sparing Tetrahydropyranyl and piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis and cardiovascular disease. J. Med. Chem. 2010, 53, 6653-6680.